Kornimate/medical-research-clean huggingface dataset:
randomized clinical trial on transanal irrigation

Conditions: Low Anterior Resection Syndrome

Summary: objective the primary objective is to demonstrate superiority of the peristeen cone catheter compared to standard of care. the secondary objective is to investigate quality of life and different benefits and aspects of treatment and satisfaction with the peristeen cone catheter. design of the investigation this is a randomised, open-label, parallel investigation comparing the peristeen cone catheter with standard of care in subjects with major lars (lars score ≥ 30). each subject will be enrolled for a study duration of 12 weeks. subjects will be randomized to the treatments stratified by neo-adjuvant radiotherapy. the comparator in this study will be current standard of care for patients with lars which is conservative bowel management. this is defined as: supportive therapy according to the individual treatment protocols available at each participating site. primary endpoint and secondary endpoints primary endpoint: • lars score, obtained from the lars score questionnaire\* secondary endpoints: * number of subjects with major lars\* * fiql score - scale 1, modified american society for colorectal surgeons questionnaire\* * fiql score - scale 2, modified american society for colorectal surgeons questionnaire\* * fiql score - scale 3, modified american society for colorectal surgeons questionnaire\* * fiql score - scale 4, modified american society for colorectal surgeons questionnaire\* * eq-5d-5l - utility score\* * eq-5d-5l - vas score (scale 0-10 cm)\* * satisfaction with treatment (scale 0-10 cm)\* * number of adverse events\* \*all endpoints are measured per subject at study completion


Eligibility criteria:
inclusion criteria: 1. be at least 18 years of age and have full legal capacity 2. have given written informed consent 3. be mental and physical capable to perform transanal irrigation with cone catheter 4. have a lars score ≥ 30 after rectal resection 5. be treated according to individual treatment protocol for conservatory bowel management at participating site 6. have proof of complete healing of the anastomosis by endoscopy or radiology before stoma closure 7. at least 3-months from last surgery in colorectum 8. be evaluated to be suitable for transanal irrigation procedure with a cone catheter by endoscopy, defecography or comparable procedure exclusion criteria: 1. active/recurrent colorectal cancer 2. leaking anastomosis 3. known anal or colorectal stenosis 4. within 4 weeks of endoscopic polypectomy 5. ischaemic colitis 6. acute inflammatory bowel disease 7. acute diverticulitis 8. current or planned pregnancy
effect of nutritional formula supplementation on growth of prepubertal children treated with stimulants medications for attention deficit hyperactivity disorder (adhd)

Conditions: ADHD - Attention Deficit Disorder With Hyperactivity

Summary: the proposed study is a double blind, randomized, placebo controlled study. the aim of the study is to evaluate the effect of nutritional formula supplementation on growth of prepubertal children treated with stimulants medications of adhd. 70 participants treated with stimulants medications of adhd will be randomly assigned either to the intervention group or the placebo control group. randomization for the two study groups will be made in a ratio of 1:1. both participants and study team will be blinded to the type of treatment that each patient will receive during the study. randomization will be stratified according to gender. participants in the intervention groups will be treated with the study formula and participants in the control group will be treated with a placebo low caloric formula (powder added to water). the study will continue for 6 months of intervention versus active placebo, with additional 6 months (an extension period), in which participants at both groups, the intervention and the placebo, will be offered to continue their participation in the study with the active study supplement. in addition, 30 prepubertal healthy siblings will be recruited to the study in order to compare baseline eating and physical activity patterns of adhd children treated with stimulants to their healthy untreated siblings at the same age range. participants' siblings will only complete once the nutritional and physical activity questionnaire and report height and weight measurements.


Eligibility criteria:
inclusion criteria: 1. boys aged ≤ 10 years and girls aged ≤ 9 years. 2. children treated with stimulants medications for adhd for at list 3 months. 3. prepubertal -tanner stage 1 (gonadarche) (boys: testicular volume \< 4, girls: breast at tanner stage 1) 4. normal weight status: bmi-sds ≤ 85th percentile for age and gender according to the cdc 2000 growth charts 5. signing inform consent forms exclusion criteria: 1. diagnosis of gh deficiency or treatment with gh 2. any known chronic disease or dysmorphic syndrome including bone diseases, organic brain diseases, neurological disease, past or current malignancy, chronic cardiac, renal or pulmonary problems 3. any known gastrointestinal disease including malabsorption 4. any known organic reason for growth retardation 5. milk allergy. 6. any chronic treatment with additional medication beside stimulants that might affect appetite, weight, or growth (for example ssri's).
ph i safety and efficacy of odsh in patients receiving induction or consolidation therapy for acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: this is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of odsh (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid leukemia.


Eligibility criteria:
inclusion criteria: * newly diagnosed, previously untreated acute myeloid leukemia. acute promyelocytic leukemia is excluded. * no prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to control white blood cell count is allowed. * no prior chemotherapy or lenalinomide for treatment of myelodysplastic syndrome. * age: 18-70. * ecog performance status 0-2 * cardiac ejection fraction ≥ 50% (echocardiography or muga \[multigated acquisition\]) * adequate hepatic and renal function (ast \[aminotransferase\], alt \[alanine aminotransferase\], bilirubin and creatinine \< 2.5 x upper normal limit). * able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines. exclusion criteria: * patients with acute promyelocytic leukemia * patients with acute megakaryoblastic leukemia * patients with cns (central nervous system) leukemia * presence of significant active infection or uncontrolled bleeding * any coexisting major illness or organ failure which contraindicates the dose-intensive chemotherapy regimen prescribed by this protocol * pre-existing liver disease that might impair odsh clearance * history of other active malignant disease within 5 years, other than cured basal cell carcinoma of the skin, cured in situ carcinoma of the cervix, or localized prostate cancer that has received definitive therapy. such prostate cancer patients who are receiving hormonal therapy are eligible * use of recreational drugs or history of drug addiction, within the prior 6 months * known history of positive hepatitis b surface antigens or hepatitis c antibodies * known history of positive test for hiv (human immunodeficiency virus) antibodies * psychiatric or neurologic conditions that could impair ability to give proper informed consent * presence of symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia * presence of uncontrolled thrombotic or hemorrhagic disorder * a medical condition that requires the need to be on chronic anticoagulation * presence of any other serious uncontrolled medical disorder * treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry * pregnant or breast-feeding patients * patient with childbearing potential not using adequate contraception * hemorrhage risk that requires maintenance of platelet counts at 50,000/ul or higher. * any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
genotype and susceptibility to covid-19

Conditions: Covid19

Summary: covid-19 is a viral disease induced by infection with the novel sars-cov-2 coronavirus. infection arises from the inhalation of viral particles spread by an infected individual. the main virus entry pathways are the nose and mouth mucous membranes, particularly rich in ace2 receptors, that are used by the virus to enter cells and begin its replication. not all individuals who contract the virus fall ill, and most of those who do (about 70-80%) experience mild symptoms (fever, cough, headache, muscle aches, loss of taste and smell). if the immune system is unable to rapidly fight the virus back, the latter can attack the lungs, affeting oxygen absorption inside the alveoli and lead to pneumonia. this more severe form is observed in 20% of patients and can develop into even more serious complications requiring intensive care, with a high mortality rate. in severe cases (about 5%), the disease spreads to the entire body reaching the cardiovascular system and brain, with the risk of heart attacks, encephalitis and stroke, but it can also affect the liver, kidney and bowel. reasons why some subjects develop a highly severe disease while others have little or no symptoms at all still remain unclear. many researchers are trying to find an answer by investigating the human genome, and the mario negri laboratories are also working in this direction. the general hypothesis underlying this research project is that inter-individual genetic variations can explain the different responses to viral infection in a population, and that covid-19 severity is, therefore, genetically determined in each infected subject.


Eligibility criteria:
inclusion criteria: - age \> 18 years exclusion criteria: none

Keywords: covid-19 genotype
super chinese nephrotic syndrome registration system (success)

Conditions: Nephrotic Syndrome

Summary: the investigators are registering all nephrotic syndrome (ns) patients regardless of the primary causes and developing a ns database in china. patients will be followed-up and both baseline and follow-up information will be recorded in the registration system. the treatment response, longitudinal changes of renal function, renal survival, patient survival, infection events and acute kidney injury etc, will be analyzed using the ns database.

the investigators are registering all ns patients regardless of the primary causes in china. patients' demographic characteristics (including age, gender, height, weight, bmi, smoking, drinking, and education), clinical characteristics (including systolic blood pressure, diastolic blood pressure, primary cause of ns, and lab measurements of serum, urine), pathological characteristics, treatment and treatment response, complications and outcomes. patients will be followed up, the demographic, clinical characteristics, treatment, lab tests of blood and urine and complications of patients will be collected and recorded at each visit. the investigators also record the outcome at each visit, such as treatment response, longitudinal changes of renal function, hospitalization, occurrence of infection or cardiovascular events etc. the outcomes will be analyzed using the ns database.

Eligibility criteria:
inclusion criteria: * nephrotic syndrome patients regardless of the primary causes exclusion criteria: * no

Keywords: nephrotic syndrome treatment response renal function
asthma and obesity: observational

Conditions: Asthma; Obesity

Summary: obesity is associated with poor asthma control and greater healthcare utilization and costs. in this study the researchers will examine the biologic and behavioral interrelationships between these conditions and their impact on outcomes. towards this end, the researchers will conduct an observational prospective cohort study of 400 obese asthmatic patients treated at institutions in new york city and denver, and develop and pilot test educational and counseling modules that take an integrated approach to asthma and obesity self-management support.

the objective of this study is to examine novel biological and behavioral pathways that may explain the association of obesity with asthma morbidity, and develop and pilot test educational and counseling modules, based on self-regulation theory, that take an integrated approach to asthma and obesity self-management support. the specific aims are to: 1. compare the longitudinal relationship between l-arginine/adma balance and morbidity (lung function, asthma control, acute resource utilization, and quality of life) between obese adults with late onset asthma vs. (a) obese adults with early onset asthma and non-obese asthmatics with early (b) or late (c) onset disease. age of asthma onset is as categorized as early when developed ≤12 years of age or late when developed \>12 years of age. 2. evaluate the interrelationship between obesity- and asthma-related illness beliefs, and the impact of cognitive function, on patients' management of these conditions over time

Eligibility criteria:
inclusion criteria: * \>21 years with a diagnosis of asthma made by a health care provider and evidence of airway reactivity (increase in fev1 \>12% and \>200 ml after bronchodilators or positive methacholine test) in prior lung function testing or baseline spirometry; * prescribed an asthma controller medication; * english or spanish speaking. exclusion criteria: * chronic obstructive lung disease (copd) or other chronic respiratory illness; - \>15 pack-year smoking history because of the possibility of undiagnosed copd; * diagnosis of dementia identified in the clinical record.

Keywords: asthma obesity observational study
the relationship between hormone sensitivity and imaging of idiopathic interstitial pneumonia by artificial intelligence

Conditions: Idiopathic Interstitial Pneumonia

Summary: application of artificial intelligence deep learning algorithm to analyze the relationship between hormone sensitivity of idiopathic interstitial pneumonia and imaging features of high resolution ct.

methods: the medical records and chest high-resolution ct images of patients with idiopathic interstitial pneumonia admitted to the respiratory department of the third hospital of peking university from june 1, 2012 to december 31, 2020 were retrospectively analyzed.application of artificial intelligence deep learning neural convolution network method to create recognition technology of different imaging features.including ground glass, mesh, honeycomb, nodule or consolidation, the model was established. iip patients were divided into hormone sensitive group and hormone insensitive group according to whether the use of hormone was effective or not.logistic regression analysis was used to analyze the correlation between statistically significant parameters and hormone sensitivity.artificial intelligence was used to establish the correlation model between imaging features and clinical data and hormone sensitivity.

Eligibility criteria:
inclusion criteria: clinical-pathological-radiology diagnosis of idiopathic interstitial pneumonia hormone therapy was used; the follow-up data were complete, and the effect of hormone use could be judged. exclusion criteria: lung infection disease; heart failure; connective tissue disease; iip without hormone therapy ; iip but the follow-up data were incomplete, and the effect of hormone use could not be judged.

Keywords: hormone sensitivity imaging features artificial intelligence
study of the biological function of muscle satellite cells from patients with obstetric brachial plexus palsy

Conditions: Obstetrical Brachial Plexus Palsy

Summary: the purpose of this prospective work is to study the consequences of obstetrical brachial plexus paralysis on the rotator muscles of the shoulder. the hypothesis is that shoulder stiffness of these children is due to an impairment of the shoulder rotator muscles. the investigators want to test the regenerative capacities of these muscles. the development of a cellular model of this pathology will allow to test new therapeutic perspectives and to validate our hypothesis.

during delivery, there can be a lesion of the nerve roots of the brachial plexus (cervical c5-c8 and/or thoracic t1 roots). the newborn presents at birth a paralysis of the arm (obstetrical brachial plexus paralysis: obpp). one third of children with obpp will have sequelae despite daily rehabilitation. the most frequent disability is shoulder stiffness. the current hypothesis is that this stiffness is due to a permanent imbalance between the affected shoulder muscles (lateral rotators) and the muscles less affected by the paralysis (medial rotators). because of this imbalance, the injured shoulder is spontaneously positioned in medial rotation. this position would lead to retractions at the front of the joint despite rehabilitation. in case of incomplete recovery, growth disorders of the shoulder joint (dysplasia) appear as well as a functional handicap. the management, from the age of 2 years, in case of shoulder stiffness and dysplasia, is surgery (arthrolysis) to regain mobility. during this operation, a muscle transfer can also be performed to strengthen the lateral rotator muscles. however, despite surgery, mobility deficits often recur within a few years. to understand the origin of the lateral and medial rotation deficits, the investigators conducted an anatomopathological study of the rotator muscles in these children. the preliminary results show a significant damage of the rotator muscles with the presence of fibrosis which could explain the rotational stiffness and the functional impairment. to better understand the pathophysiological mechanisms, the investigatorswill set up an obpp model in cell culture to understand the regenerative capacities and to test new pharmacological approaches.

Eligibility criteria:
inclusion criteria: * obpp children with a planned shoulder surgery (arthrolysis and/or muscle transfer). exclusion criteria: * other neurological disorders, post-traumatic shoulder stiffness

Keywords: brachial plexus neonatal brachial plexus palsy denervation muscle atrophy muscle regeneration botulinum toxin satellite cell primary human muscle cell culture
evaluation of radiation induced pulmonary hypertension using mri in stage iii nsclc patients treated with chemoradiotherapy. a pilot study

Conditions: Pulmonary Hypertension

Summary: in the radiotherapeutic treatment of lung cancer, the dose that can be safely applied to the tumour is limited by the risk of radiation induced lung damage. this damage is characterized by parenchymal damage and vascular damage. in rats, we have found that radiation-induced vascular damage results in increased pulmonary artery pressure. interestingly, the consequent loss of pulmonary function could be fully explained by this increase in pulmonary artery pressure. we hypothesize that also in patients a radiation induced increase in pulmonary artery pressure can be observed after radiotherapy, which may contribute to the development of radiation pneumonitis. the objective is to test the hypothesis that radiotherapy for lung cancer induces an increase in pulmonary artery pressure.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * who ps 0-2 * histological or cytological confirmation of non-small cell lung cancer or an 18f-fdg-positive, growing mass on ct-thorax suggestive of nsclc. * stage iiia or iiib * patients with extensive mediastinal lymph node involvement (such as n3), or large primary tumour size * adequate pulmonary function estimated by flow volume curves * life expectancy of at least 6 months * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol; those conditions should be discussed with the patient before registration in the trial. * planned for 25 x 2.4 gy, with concomitant chemotherapy * before patient registration, written informed consent will be obtained. exclusion criteria: * presence of contra-indications for undergoing mri

Keywords: pulmonary hypertension cardiac mrt radiotherapy
the efficacy of casad in patients with diarrhea related to medullary thyroid cancer

Conditions: Diarrhea; Medullary Thyroid Cancer

Summary: diarrhea in patients with mtc (medullary thyroid cancer) can be debilitating and, in some cases life threatening. findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. diarrhea can also lead to increased cost of care, reduced quality of life, and treatment delays. not all patients benefit from conventional anti-diarrheal therapy. casad is proven to reduce diarrhea in humans and animals. clays have water-binding effects, increase the absorptive capacity of the intestinal mucosa, and absorb the excess cytokines which are possible mechanisms of diarrhea in mtc. in this study, we will investigate if starting 1 g casad three times a day will ameliorate the severity of diarrhea in patients with mtc. diarrhea in patients with mtc can be debilitating and, in some cases life threatening. findings in such patients include volume depletion, renal insufficiency, and electrolyte disorders. we hypothesize that adding casad 3 grams/day will reduce the incidence and ameliorate the severity of diarrhea in patients with mtc.


Eligibility criteria:
inclusion criteria: * patients with medullary thyroid cancer * men and women from all ethnic and racial groups * diarrhea ( \>=3 loose bowel movements per day) * duration of diarrhea of at least 1 week exclusion criteria: * patients with men 2b (since these patients may have megacolon) * patients taking any clay products * history of significant neurological or psychiatric disorders that would impede giving consent, treatment, or follow up. * patients who cannot comply with medications * patients whose current medication schedule would not permit an approximate 2 hour window between administration of casad and other scheduled medications. * pregnancy or lactation * patients receiving systemic chemotherapy (includes tyrosine kinase inhibitors)

Keywords: diarrhea medullary thyroid cancer